Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL909133 | 1.00 | KDM4E (0.33) | — | |
| Methyl Alcohol SCHEMBL11583267 | 0.95 | — | — | |
| SCHEMBL3793 | 0.95 | — | — | |
| Water SCHEMBL5185846 | 0.90 | — | — | |
| Bromide SCHEMBL3798899 | 0.90 | — | — | |
| Methyl Alcohol SCHEMBL11662814 | 0.90 | — | — | |
| Methyl Alcohol SCHEMBL11568348 | 0.86 | — | — | |
| SCHEMBL28613907 | 0.86 | — | — | |
| SCHEMBL9366540 | 0.82 | ALDH1A1 (0.33) | — | |
| Tromethamine SCHEMBL8530527 | 0.77 | MEN1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115247170-A | Viral nucleic acid extraction kit based on paramagnetic particle method and automatic operation program | 上海绅道生物科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-112243371-A | Compositions and methods for treating skin lesions | 斯科特·大卫·格雷泽 | 2021-01-19 | — | — | CN | claimed |
| US-4959213-A | Pharmaceutical composition for treatment and/or prevention of diseases of the skin involving an inflammatory process | L'OREAL (FR) | 1990-09-25 | — | — | US | claimed |
| US-20260144861-A1 | COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION | BioNTech SE (DE) | 2026-05-28 | — | — | US | disclosed |
| US-12247979-B2 | Compositions and methods for capturing exosomes | MOREHOUSE SCHOOL OF MEDICINE | 2025-03-11 | — | — | US | disclosed |
| EP-4419901-A1 | HIGH-THROUGHPUT MULTIPLEXING ELECTROPHORETIC GEL APPARATUS AND RELATED METHODS | Zadeh, Cameron O. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240090494-A1 | PERFUSION SOLUTION | ORGAN TRANSP PTY LTD (AU) | 2024-03-21 | — | — | US | disclosed |
| CN-111182880-B | WNT compositions and process from serum-free culture conditions | 安卡萨再生疗法公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11788040-B2 | Diagnostic device and related method | EMPE DIAGNOSTICS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| CN-116445398-A | WNT composition and purification method | 小利兰斯坦福大学托管委员会 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023069756-A1 | HIGH-THROUGHPUT MULTIPLEXING ELECTROPHORETIC GEL APPARATUS AND RELATED METHODS | ZADEH CAMERON O (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-0192811-A1 | Cysteine-depleted muteins of biologically active proteins, their preparation, formulations containing them, and structural genes, vectors and organisms, and their production, suitable for use in the preparation of said muteins | CETUS ONCOLOGY CORPORATION (US) | 1986-09-03 | — | — | EP | disclosed |
| US-4606917-A | Synergistic antiviral composition | SYNTEX (U.S.A) INC. (US) | 1986-08-19 | — | — | US | disclosed |
| US-4588585-A | Human recombinant cysteine depleted interferon-β muteins | CETUS CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| US-4518584-A | CYSTEINE 125 REPLACED BY NEUTRAL AMINO ACID | CETUS CORPORATION (US) | 1985-05-21 | — | — | US | disclosed |
| EP-0109748-A1 | Pharmaceutical and veterinary preparations of cystein-125-depleted muteins of Interleukin-2 and their production | CETUS CORPORATION (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0080021-A2 | Haemophilus influenzae type B and pertussis outer membrane component combined vaccine | AMERICAN CYANAMID COMPANY (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0016546-A1 | Extracellular microbial lipoheteropolysaccharides and derivatives, their preparation and compositions containing them, and their uses | Petroleum Fermentations N.V. (AN) | 1980-10-01 | — | — | EP | disclosed |
| US-4119521-A | Fluorescent derivatives of activated polysaccharides | Turner, Stephen (US) | 1978-10-10 | — | — | US | disclosed |
| US-3957584-A | Detection of beta-galactosidase producing micro-organisms | WARNER-LAMBERT COMPANY (US) | 1976-05-18 | — | — | US | disclosed |